Author

Toju Sillo

University of Birmingham

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Research Focus:variant calling· 2 Assay:whole-genome sequencing· 2

Frequent Co-Authors

Andrew David BeggsiD· 2 shared Agata Stodolna· 1 shared Daniel BlakewayiD· 1 shared Gary MiddletoniD· 1 shared Gerald MartiniD· 1 shared Jean‐François Laes· 1 shared Jennifer Becq· 1 shared Joanne StocktoniD· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Andrew David BeggsORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Clinical-grade whole genome sequencing of colorectal cancer and 3-prime transcriptome analysis demonstrate targetable alterations in the majority of patients.

Agata Stodolna, Miao He, Mahesh Vasipalli, Zoya Kingsbury, Jennifer Becq, Joanne Stockton, Mark Dilworth, Jonathan James, Toju Sillo, Daniel Blakeway, Steve Ward, Tariq Ismail, Mark T. Ross, Andrew David Beggs

The paper uses clinical-grade whole genome sequencing and 3' transcriptome analysis to identify targetable genomic alterations in colorectal cancer patients.

Genome Medicine · Feb 25, 2021Peer-reviewedGenetic & Genomic Medicine

Use of an integrated pan-cancer oncology enrichment NGS assay to measure tumour mutational burden and detect clinically actionable variants

Valerie Pestinger, Matthew Ryan Smith, Toju Sillo, John M. Findlay, Jean‐François Laes, Gerald Martin, Gary Middleton, Phillipe Taniere, Andrew David Beggs

The paper evaluates the TruSight Oncology 500 assay for measuring tumour mutational burden and detecting clinically actionable variants, showing strong correlation with whole genome sequencing and orthogonal methods.

Molecular Diagnosis & Therapy · Apr 18, 2020Peer-reviewedGenetic & Genomic Medicine